Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cardiac hypertrophy associated with myeloproliferative neoplasms in JAK2V617F transgenic mice.

Journal of hematology & oncology - 19 Mar 2014

Shi Kaiyao, Zhao Wanke, Chen Yun, Ho Wanting Tina, Yang Ping, Zhao Zhizhuang Joe

Abstract excerpt

BACKGROUND: Myeloproliferative neoplasms (MPNs) are blood malignancies manifested in increased production of red blood cells, white blood cells, and/or platelets. A major molecular lesion associated with the diseases is JAK2V617F, an activation mutation form of tyrosine kinase JAK2. Cardiovascular events represent the leading cause of morbidity and mortality associated MPNs, but the underlying mechanism is not...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cardiomegaly
Share to Fibrosis
Share to Hematologic Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Janus Kinase 2

Share to Mice, Inbred C57BL

Share to Mice, Transgenic

Share to Myeloproliferative Disorders

Source

Open in PubMed Open full text

Identifiers

PMID: 24646493
DOI: 10.1186/1756-8722-7-25
PMCID: PMC3995113

Genes

JAK2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cardiac hypertrophy associated with myeloproliferative neoplasms in JAK2V617F transgenic mice.PMID 24646493Read ↗

Endothelial JAK2V617F mutation leads to thrombosis, vasculopathy, and cardiomyopathy in a murine model of myeloproliferative neoplasmSemantic proximity Read ↗

Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice.Semantic proximity Read ↗

Endothelial JAK2V617F mutation leads to thrombosis, vasculopathy, and cardiomyopathy in a murine model of myeloproliferative neoplasm.Semantic proximity Read ↗

Overview of Transgenic Mouse Models of Myeloproliferative Neoplasms (MPNs).Semantic proximity Read ↗

[Myeloproliferative neoplasms and vascular diseases].Semantic proximity Read ↗

Clonal hematopoiesis and cardiovascular diseases: role of JAK2V617F.Semantic proximity Read ↗

Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice.Semantic proximity Read ↗

Targeting TPO/MPL Signaling to Mitigate JAK2V617F-driven Cardiac Microvascular DiseaseSemantic proximity Read ↗

Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera–like diseaseSemantic proximity Read ↗

A murine model with JAK2V617F expression in both hematopoietic cells and vascular endothelial cells recapitulates the key features of human myeloproliferative neoplasmSemantic proximity Read ↗

Cardiac JAK2 mutation V617F in a patient with cardiomyopathy and myeloproliferative disease.Semantic proximity Read ↗

Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.